Market Place
Sourcing Support
Zura Bio Launches Phase 2 Tibusure Study for Systemic Sclerosis
23 Dec 2024 //
BUSINESSWIRE
Zura Bio to Present at Piper Sandler 36th Annual Health Conference
25 Nov 2024 //
BUSINESSWIRE
Zura Bio Submits Protocol to FDA for Ph 2 in Systemic Sclerosis
14 Nov 2024 //
BUSINESSWIRE
Zura Bio Reports Q3 2024 Financial Results & Corporate Updates
07 Nov 2024 //
BUSINESSWIRE
Zura Bio to Present at Two November Investor Conferences
30 Oct 2024 //
BUSINESSWIRE
Zura Bio to Present at Three Upcoming Investor Conferences in September
03 Sep 2024 //
BUSINESSWIRE
Zura Bio Reports Q2 2024 Results And Recent Business Highlights
13 Aug 2024 //
BUSINESSWIRE
Zura Bio Completes Exchange Offer And Warrant Exercise
12 Aug 2024 //
BUSINESSWIRE
Zura Bio Announces Results Of Warrant Exchange Offer
09 Aug 2024 //
BUSINESSWIRE
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
12 Jul 2024 //
BUSINESSWIRE
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
14 Jun 2024 //
BUSINESSWIRE
Zura Bio Forms SAB With Rheumatology, Dermatology, Immunology Experts
06 Jun 2024 //
BUSINESSWIRE
Zura`s Tibulizumab Potential In Sjogren`s, RA At EULAR 2024
03 Jun 2024 //
BUSINESSWIRE
Zura Bio Announces Participation in June Investor Conferences
29 May 2024 //
BUSINESSWIRE
Zura Bio Q1 2024 Financials, Business Highlights
09 May 2024 //
BUSINESSWIRE
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
18 Apr 2024 //
BUSINESSWIRE
Zura Bio Announces Robert Lisicki as CEO and Director
08 Apr 2024 //
BUSINESSWIRE
Zura Reports Full Year 2023 Financial Results & Appoints Robert Lisicki as CEO
28 Mar 2024 //
BUSINESSWIRE
Zura Bio Announces Participation at March Conferences
04 Mar 2024 //
BUSINESSWIRE
Zura Bio Announces Participation at February Investor Conferences
02 Feb 2024 //
BUSINESSWIRE
Zura Bio Continues to Strengthen Leadership
08 Jan 2024 //
BUSINESSWIRE
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Zura Bio Announces Two Immunology Abstracts Presented
04 Dec 2023 //
BUSINESSWIRE
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
14 Nov 2023 //
BUSINESSWIRE
Zura Bio Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
Zura Completes $80M Financing with the Focus on Advancing ZB-106
06 Jun 2023 //
BUSINESSWIRE
Zura Bio Announces $80 M Financing and the Licensing of Tibulizumab (ZB-106)
27 Apr 2023 //
BUSINESSWIRE
Zura Bio Names Michael Howell Chief Scientific Officer
14 Apr 2023 //
CONTRACT PHARMA
Zura Bio Limited Announces Share Redemptions and Lock-up Agreement
27 Mar 2023 //
BUSINESSWIRE
Zura Bio Announces Closing of Business Combination with JATT Acquisition Corp
21 Mar 2023 //
BUSINESSWIRE
JATT Acquisition Corp’s Proposed Business Combination With Zura Bio
02 Mar 2023 //
BUSINESSWIRE
